Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: new reality with new challenges

Malignant pleural mesothelioma (MPM) is a rare and orphan thoracic malignancy, accounting for 2.1 cases per 100,000 people per year, and including epithelioid, sarcomatoid and biphasic histologic subtypes [1]. MPM is usually diagnosed at advanced stages due to the absence of early symptoms, and the diffuse nature of the disease combined with lack of sensitivity to chemotherapy may reduce the options for radical-curative approaches. While we are witnessing years of exciting progress for patients with advanced lung cancer, limited therapeutic improvements have been made in unresectable MPM since the approval of platinum-pemetrexed in 2004 as the backbone chemotherapy strategy [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research